# EDGAR Filing Document

**Accession Number:** 0002057997
**File Stem:** 0001213900-26-053091
**Filing Date:** 2026-5
**Character Count:** 15053
**Document Hash:** da17be8342ef0525caf4255140f3e686
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-053091.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001213900-26-053091

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apimeds Pharmaceuticals US, Inc.
- **CENTRAL INDEX KEY:** 0001894525
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851099700
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95043
- **FILM NUMBER:** 26951189

**BUSINESS ADDRESS:**
- **STREET 1:** 100 MATAWAN RD
- **STREET 2:** SUITE 325
- **CITY:** MATAWAN
- **STATE:** NJ
- **ZIP:** 07747
- **BUSINESS PHONE:** 848-201-5010

**MAIL ADDRESS:**
- **STREET 1:** 100 MATAWAN RD
- **STREET 2:** SUITE 325
- **CITY:** MATAWAN
- **STATE:** NJ
- **ZIP:** 07747
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inscobee Inc.
- **CENTRAL INDEX KEY:** 0002057997

**ORGANIZATION NAME:**
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 613, DIGITAL-RO 130, 6F
- **STREET 2:** GEUMCHEON-GU
- **CITY:** SEOUL
- **STATE:** M5
- **ZIP:** 08580
- **BUSINESS PHONE:** 82-70-7600-7007

**MAIL ADDRESS:**
- **STREET 1:** ROOM 613, DIGITAL-RO 130, 6F
- **STREET 2:** GEUMCHEON-GU
- **CITY:** SEOUL
- **STATE:** M5
- **ZIP:** 08580

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Apimeds Pharmaceuticals US, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**You In Soo, CEO**<br>Room 613, Digital-ro 130<br>6F Geumcheon-gu<br>Seoul M5 08580<br>82-70-7600-7007

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/07/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Inscobee Inc.** | Name of reporting person<br>**Inscobee Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2099747.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2099747.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2099747.00** | Aggregate amount beneficially owned by each reporting person<br>**2099747.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**16.7%** | Percent of class represented by amount in Row (11)<br>**16.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1) The percentage in Row 13 is based on 12,575,983 shares of common stock, par value $0.01 per share (the "Common Stock"), of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "Issuer") outstanding as of April 30, 2026, as reported by the Issuer in its Annual Report on Form 10-K filed on May 4, 2026 (the "Annual Report").

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Apimeds Inc.** | Name of reporting person<br>**Apimeds Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4316618.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4316618.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4316618.00** | Aggregate amount beneficially owned by each reporting person<br>**4316618.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**34.3%** | Percent of class represented by amount in Row (11)<br>**34.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1) The percentage in Row 13 is based on 12,575,983 shares of Common Stock outstanding as of April 30, 2026, as reported by the Issuer in the Annual Report.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Apimeds Pharmaceuticals US, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
100 Matawan Road, Suite 325, Matawan, NJ, 07747

This Amendment No. 4 to the Schedule 13D (this "Amendment No. 4") relates to the shares of common stock, par value $0.01 per share (the "Common Stock"), of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "Issuer"), and amends the Schedule 13D filed on May 19, 2025 (the "Original Schedule 13D"), Amendment No. 1 to Schedule 13D filed on January 26, 2026 ("Amendment No. 1"), Amendment No. 2 to Schedule 13D filed on March 20, 2026 ("Amendment No. 2") and Amendment No. 3 to Schedule 13D on March 25, 2026 ("Amendment No. 3) by Inscobee Inc. ("Inscobee") and Apimeds Inc. ("Apimeds Korea" and together with Inscobee, the "Reporting Persons") as set forth herein.

**Item 4. Purpose of Transaction**

The information set forth in Item 3 of the Schedule 13D is incorporated herein by reference.

The Reporting Persons acquired the securities of the Issuer for investment purposes.

As previously disclosed, the Reporting Persons engaged in discussions and disputes with the Issuer and certain other parties in connection with, among other things, the Merger Agreement, the Support & Lock-Up Agreement, the Voting Agreements and related transactions.

On April 24, 2026, the Reporting Persons and certain other parties entered into a Settlement Agreement (the "Settlement Agreement"), as disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 4, 2026 (the "Current Report"), pursuant to which the parties agreed to resolve certain disputes relating to the Issuer, the Merger and related transactions.

In connection with the Settlement Agreement, the Reporting Persons and certain other parties also entered into (i) a Side Letter Agreement (the "Side Letter") and (ii) a Forbearance Agreement (the "Forbearance Agreement," and together with the Settlement Agreement and Side Letter, the "Settlement Documents"), each as described in the Current Report.

The Settlement Documents provide for, among other things:

- the resolution of disputes among the parties relating to the Merger and related transactions;

- the dismissal of certain litigation and release of claims related to the Merger Agreement, including the dismissal by Erik Emerson of the lawsuit previously filed against the Reporting Persons and/or the Issuer;

- the modification of certain prior agreements and arrangements among the parties, including the removal of certain alleged events of default asserted against the Reporting Persons under prior agreements; and

- certain governance, voting and other arrangements among the parties.

Pursuant to the Settlement Documents, the Reporting Persons granted an irrevocable proxy (the "Irrevocable Proxy") to Dr. Vin Menon and Captain Sandeep Singh Yadav, pursuant to which such person is entitled to vote the shares of Common Stock beneficially owned by the Reporting Persons with respect to certain matters specified therein. The Irrevocable Proxy is coupled with an interest and is intended to be irrevocable until the later of (x) 30 days following the receipt of NYSE approval of the Listing Application, (y) the completion of the Preferred Stock Conversion and Note Approval following such NYSE approval or (z) the date on which NYSE provides a final, non-appealable denial or rejection of the application for such approval; or (aa) July 30, 2026.

The foregoing description of the Irrevocable Proxy does not purport to be complete and is qualified in its entirety by reference to the full text of the applicable agreement.

As previously disclosed, the Reporting Persons had raised concerns regarding the existence and ownership of certain digital assets, including bitcoin, purportedly held by or on behalf of the Issuer or its affiliates in connection with the Merger and related transactions.

Following further review and investigation, including consideration of information provided to the Reporting Persons and confirmations obtained by independent auditors, the Reporting Persons have been advised that (i) a Public Company Accounting Oversight Board-registered public accounting firm engaged in connection with the Merger verified the existence of approximately 1,000 bitcoin on multiple occasions, and (ii) an additional independent PCAOB-registered public accounting firm engaged in connection with the Issuer's Annual Report on Form 10-K independently verified such bitcoin holdings.

Based on the foregoing, the Reporting Persons are satisfied that their prior concerns regarding the existence of such digital assets have been addressed.

The foregoing descriptions are qualified in their entirety by reference to the full text of the Settlement Documents, which are incorporated herein by reference.

As a result of the execution of the Settlement Documents, the Reporting Persons' prior actions and potential plans relating to, among other things, litigation, removal of directors and other extraordinary corporate actions have been resolved or modified as set forth therein.

The Reporting Persons currently intend to act in accordance with the Settlement Documents and, except as set forth therein, do not have any present plans or proposals that relate to or would result in any of the matters described in Item 4(a)-(j) of Schedule 13D.

The Reporting Persons reserve the right to review their investment in the Issuer and to take such actions as they deem appropriate, subject to the terms of the Settlement Documents.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Persons have granted an irrevocable proxy pursuant to the Settlement Documents described in Item 6, which provides the proxy holder with the right to vote the shares of Common Stock beneficially owned by the Reporting Persons with respect to certain specified matters. As a result, the Reporting Persons may be deemed to share voting power with respect to such shares for purposes of Rule 13d-3 under the Exchange Act. The Irrevocable Proxy is coupled with an interest and is intended to be irrevocable until the later of (x) 30 days following the receipt of NYSE approval of the Listing Application, (y) the completion of the Preferred Stock Conversion and Note Approval following such NYSE approval or (z) the date on which NYSE provides a final, non-appealable denial or rejection of the application for such approval; or (aa) July 30, 2026.

**(b)**
—

**(c)**
—

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The information set forth in Items 3, 4, 5 and 7 of this Amendment No. 4 is incorporated herein by reference.

On April 28, 2026, the Reporting Persons entered into the Settlement Agreement, Side Letter and Forbearance Agreement, as described in Item 4 above and in the Current Report.

The Settlement Documents contain various agreements, arrangements and understandings with respect to the securities of the Issuer, including, without limitation:

- governance arrangements relating to the Issuer's board of directors;

- voting commitments and/or restrictions;

- standstill provisions;

- transfer restrictions and/or lock-up provisions; and

- releases and waivers of claims.

To the extent applicable, the Settlement Documents modify, supersede or terminate certain prior agreements described in prior amendments to the Schedule 13D, including, without limitation, the Support & Lock-Up Agreement and the Voting Agreements.

The foregoing descriptions are qualified in their entirety by reference to the full text of the Settlement Documents.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Inscobee Inc.

**Signature:** /s/ You In Soo

**Name/Title:** You In Soo, Chief Executive Officer

**Date:** 05/07/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Apimeds Inc.

**Signature:** /s/ You In Soo

**Name/Title:** You In Soo, Chief Executive Officer

**Date:** 05/07/2026